astegolimab (RG 6149) - Amgen, Roche
Astegolimab: NME submission in US for COPD in 2025 (Roche) - Oct 23, 2024 - Q3 2024 Results: Regulatory submission in EU for COPD in 2025 
EMA filing • FDA filing Chronic Obstructive Pulmonary Disease • Immunology
https://assets.roche.com/f/176343/x/31805a2578/irp231024.pdf
 
Oct 23, 2024
 
 
6961c818-1178-4315-bc62-5a05fd5be03a.png